Perceptive And Xontogeny’s Second VC Fund Brings In $515m

Fund II Is More Than Double Their $210m Fund I In 2019

The strategy for both funds is to back companies with a preclinical drug candidate that can be advanced through clinical proof-of-concept with a mid-sized series A round. 

Wooden blocks with blue up arrows
Perceptive and Xontogeny have tripled the amount of venture capital they have under management • Source: Alamy

Perceptive Advisors and Xontogeny LLC thought their first $210m venture capital fund, known as Perceptive Xontogeny Venture Fund I (PXV Fund I), was differentiated from other VC funds, but the niche the investors sought to fill had even more demand from high-quality start-ups than anticipated. That’s one reason why, just 18 months later, they closed the $515m Perceptive Xontogeny Venture Fund II (PXV Fund II) on 12 May with more than two times the capital they raised in the first fund.

Xontogeny CEO and chairman Chris Garabedian told Scrip that “I was pleasantly surprised with the number of companies that wanted...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By 

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.